2059-75-8

Basic information

• Product Name: 1,3-bis(4-bromophenyl)thiourea
• Synonyms: 1,3-Bis(4-bromophenyl)thiourea; thiourea, N,N'-bis(4-bromophenyl)-
• CAS NO: 2059-75-8
• Molecular Formula: C₁₃H₁₀Br₂N₂S
• Molecular Weight: 386.1049
• Mol File: 2059-75-8.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 430.1°C at 760 mmHg
• Flash Point: 213.9°C
• Density: 1.837g/cm³
• Vapor Pressure: 1.33E-07mmHg at 25°C
• Refractive Index: 1.774
• CAS DataBase Reference: 1,3-bis(4-bromophenyl)thiourea(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-bis(4-bromophenyl)thiourea(2059-75-8)
• EPA Substance Registry System: 1,3-bis(4-bromophenyl)thiourea(2059-75-8)

Safety Data

• Hazardous Substances Data: 2059-75-8(Hazardous Substances Data)

Usage

Appearance

White to off-white crystalline solid

Solubility

Insoluble in water

Uses

a. Intermediate for the synthesis of pharmaceuticals and agrochemicals

Biological activity

Potential antifungal and antiparasitic properties

Research applications

Reagent for the determination of trace amounts of nickel and other metals in various samples

Hazard classification

Classified as a hazardous substance

Safety measures

Should be used in a controlled laboratory setting with appropriate safety measures

Upstream product

• 75-15-0 carbon disulfide 
• 106-40-1 4-bromo-aniline 
• 463-71-8 thiophosgene 
• 1985-12-2 4-Bromophenyl isothiocyanate 
• 93253-29-3 2-deoxy-2-(ethylamino)-L-mannose hydrochlorid 
• 333-20-0 potassium thioacyanate 
• 624-19-1 4-bromoaniline hydrochloride 
• 4314-19-6 bis(1H-benzo[d][1,2,3]triazol-1-yl)methanethione 

Downstream Products

• 726-41-0 bis(p-bromophenyl)carbodiimide 
• 75104-95-9 (6-bromo-benzothiazol-2-yl)-(4-bromo-phenyl)-amine 
• 51964-16-0 3-(4-bromophenyl)-2-(4-bromophenylimino)thiazolidin-4-one 
• 1985-12-2 4-Bromophenyl isothiocyanate 
• 42749-18-8 N-(4-bromophenyl)-2-phenylhydrazinecarbothioamide 
• 73318-41-9 N,N'-bis-(4-bromo-phenyl)-S-methyl-isothiourea 
• 35251-91-3 (4-bromo-phenyl)-[3-(4-bromo-phenyl)-3H-thiazolo[4,5-b]quinoxalin-2-ylidene]-amine 
• 35251-93-5 (4-bromo-phenyl)-[3-(4-bromo-phenyl)-7-methyl-3H-thiazolo[4,5-b]quinoxalin-3-ylidene]-amine 
• 23808-70-0 (4-bromo-phenyl)-[3-(4-bromo-phenyl)-4-phenyl-3H-thiazol-2-ylidene]-amine 
• 35251-92-4 (4-bromo-phenyl)-[3-(4-bromo-phenyl)-6-nitro-3H-thiazolo[4,5-b]quinoxalin-2-ylidene]-amine 
• 23808-75-5 (4-bromo-phenyl)-[3-(4-bromo-phenyl)-4-(4-chloro-phenyl)-3H-thiazol-2-ylidene]-amine 
• 23808-79-9 (4-bromo-phenyl)-[3-(4-bromo-phenyl)-4-(3,4-dimethoxy-phenyl)-3H-thiazol-2-ylidene]-amine 
• 20044-32-0 3-(4-bromo-phenyl)-2-(4-bromo-phenylimino)-4-methyl-2,3-dihydro-thiazole-5-carboxylic acid ethyl ester 
• 42748-46-9 (4-bromo-phenyl)-[3-(4-bromo-phenyl)-4-methyl-3H-thiazol-2-ylidene]-amine 

Relevant articles and documents

Novel non-peptidic small molecule inhibitors of secreted aspartic protease 2 (SAP2) for the treatment of resistant fungal infections

Targeting secreted aspartic protease 2 (SAP2), a kind of virulence factor, represents a new strategy for antifungal drug discovery. In this report, the first-generation of small molecule SAP2 inhibitors was rationally designed and optimized using a structure-based approach. In particular, inhibitor 23h was highly potent and selective and showed good antifungal potency for the treatment of resistant Candida albicans infections.

Nickle Catalysis Enables Access to Thiazolidines from Thioureas via Oxidative Double Isocyanide Insertion Reactions

An efficient synthesis of thiazolidine-2,4,5-triimine derivatives was developed via Ni-catalyzed oxidative double isocyanide insertion to thioureas under air conditions, in which thioureas play three roles as a substrate, a ligand, and overcoming isocyanide polymerization. The reaction is featured by employing a low-cost and low loading Ni(acac)2 catalyst, without any additives, and high atom economy. This is the first example to directly apply a Ni(II) catalyst in oxidative double isocyanide insertion reactions.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.